Mobile

A Phase II, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study, Evaluating the Efficacy and Safety of RO4607381 over a 24-week period in Patients with CHD or a CHD Risk Equivalent

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-002910-39

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To evaluate the effect of RO4607381 (900 mg daily) on HDL C in patients with CHD or a CHD risk equivalent. • To evaluate the 24-week safety profile of RO4607381. In addition to assessing the general safety profile of RO4607381, MRI imaging will be performed to evaluate potential changes in mesenteric lymph nodes.

Critère d'inclusion

  • CHD or CHD Risk Equivalent

Liens